Sponsored Symposia

Sponsored Symposia descriptions will be posted as they are confirmed. Please visit this page regularly for updated information. Click on the title of the Symposium to view the event invitation. 

Sunday, June 7

Sponsored Symposium - Hoffman-La Roche (12:00 - 13:30 EDT)

Findings from the SubCuteanous Benefit Analysis (SCuBA): A Discussion Across Canadian Institutions

Learning Objectives:

  1. Share perspectives on the impact of administration differences between the SC and IV formulations of rituximab on institutions, health care professionals, and patients;
  2. Compare the implementation experience of rituximab SC to understand successeand challenges; and
  3. Discuss the integration of SC formulations, reference biologics, and biosimilar within cancer centres from a pharmacist’s perspective.

Sunday, June 14

Sponsored Symposium - Pfizer Canada (12:00 - 13:30 EDT)

Treatment of Iron Deficiency: A New Paradigm

Christine Brezden-Masley, MD, PhD, FRCPC and Andrew Han, B. Pharm

Learning Objectives:

  1. Understand the principles and the need to treat iron deficiency anemia in cancer patients, and the rationale for rapid IV iron supplementation;
  2. Review recommendations pertaining to use of ESA for iron repletion in cancer patients;
  3. Review important clinical trials and real-world data focusing on efficient and safe administration of IV iron; and
  4. Review the safety aspects of IV iron, the formulation of iron isomaltoside, its dosage and administration.

Sponsored Symposium - Teva (13:45 - 15:15 EDT)

2020 Vision: Integration of Biosimilars in Provincial Programs

Scott J. Edwards, PharmD, MSc, Dominic Duquette, MScPhm, MBA, RPh, Jenn Gordon, Kimberly Kuik, BScPharm, and Michael LeBlanc, PharmD, FCSHP

Learning Objectives:  

  1. Understand the vision-recommendations of PCPA, pCOBI, and CCAs and assess where we currently are;
  2. Review what has been implemented so far in the provinces and hospitals (review experiences so far with implementation in Canada) and learn from previous experience of integrating biosimilars into practice;
  3. Understand the jurisdictional experience as a result of implementation of biosimilars (eg. cost-savings and any learnings or challenges from a decision-maker perspective); and
  4. Discuss what would be the next steps or milestones in 2020.

Saturday, June 20

Sponsored Symposium - Purdue Pharma (12:00 - 13:30 EDT)

Chemotherapy-Induced Nausea and Vomiting

Dr. Sandeep Sehdev

Learning Objectives:

  1. Understanding basic pathophysiology of CINV;
  2. Review the key updates from current guidelines; and
  3. Highlight the newest developments regarding contemporary management of CINV.

Sunday, June 28  

Sponsored Symposium - Pfizer Oncology (12:30 - 14:00 EDT)   

The Pharmacist Experience with Metastatic Breast Cancer (12:30 - 13:10 EDT)

Alia Thawer, PharmD, Pharmacist (Oncol)
Scott Edwards, PharmD, MSc (Oncol)

Learning Objectives:

  1. Discuss case profiles of HR+HER2-mBC patients;
  2. Share perspective on safety and tolerability of CDK4/6 inhibitors;
  3. Provide practical tips for adherence and patient education; and
  4. Review scientific data supporting the introduction of palbociclib tablet dosage form

Key Insights on Biosimilars Implementation in Oncology (13:15 - 14:00 EDT)

Flay Charbonneau, BSc Pharm, RPH
Scott Edwards, PharmD, MSc (Oncol)
Dr. Scott Berry (BSc, MD, MHSC, FRCPC)

Learning Objectives:

  1. Learn from key pharmacy and oncology experts on their challenges and lessons learned from implementing oncology biosimilars in their cancer centres;
  2. Uncover next steps for oncology biosimilars and how to best prepare;
  3. Discuss your role as a pharmacist in supporting and maintaining a sustainable oncology biosimilars environment in the future; and
  4. Learn from a medical oncologist on their clinical experience with oncology biosimilars at point of care.

Sponsored Symposium - Merck (14:15 - 15:45 EDT)    

Advanced Renal Cell Carcinoma: The Pharmacist’s Role in Managing Patients Treated with Immunotherapy Combinations

Learning Objectives:

  1. Review and discuss latest clinical data in advanced renal cell carcinoma (RCC) with a focus on first line setting;
  2. Compare and contrast immunotherapy combinations with respect to clinical endpoints and the adverse event profiles; and
  3. Discuss the pharmacist’s role within the multidisciplinary team for the management of patients with advanced RCC and share clinical experience.